Cargando…

miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC), a primary liver malignancy, is the most common cancer in males and fourth common cancer in females in Taiwan. HCC patients usually have a poor prognosis due to late diagnosis. It has been classified as a complex disease because of the heterogeneous phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales: Shyu, Yu-Chiau, Lee, Tung-Liang, Lu, Mu-Jie, Chen, Jim-Ray, Chien, Rong-Nan, Chen, Huang-Yang, Lin, Ji-Fan, Tsou, Ann-Ping, Chen, Yu-Hsien, Hsieh, Chia-Wen, Huang, Ting-Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930569/
https://www.ncbi.nlm.nih.gov/pubmed/27370270
http://dx.doi.org/10.1186/s12967-016-0956-z
_version_ 1782440761582682112
author Shyu, Yu-Chiau
Lee, Tung-Liang
Lu, Mu-Jie
Chen, Jim-Ray
Chien, Rong-Nan
Chen, Huang-Yang
Lin, Ji-Fan
Tsou, Ann-Ping
Chen, Yu-Hsien
Hsieh, Chia-Wen
Huang, Ting-Shuo
author_facet Shyu, Yu-Chiau
Lee, Tung-Liang
Lu, Mu-Jie
Chen, Jim-Ray
Chien, Rong-Nan
Chen, Huang-Yang
Lin, Ji-Fan
Tsou, Ann-Ping
Chen, Yu-Hsien
Hsieh, Chia-Wen
Huang, Ting-Shuo
author_sort Shyu, Yu-Chiau
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC), a primary liver malignancy, is the most common cancer in males and fourth common cancer in females in Taiwan. HCC patients usually have a poor prognosis due to late diagnosis. It has been classified as a complex disease because of the heterogeneous phenotypic and genetic traits of the patients and a wide range of risk factors. Micro (mi)RNAs regulate oncogenes and tumor suppressor genes that are known to be dysregulated in HCC. Several studies have found an association between downregulation of miR-122, a liver-specific miRNA, and upregulation of paternally expressed gene 10 (PEG10) in HCC; however, the correlation between low miR-122 and high PEG10 levels still remains to be defined and require more investigations to evaluate their performance as an effective prognostic biomarker for HCC. METHODS: An in silico approach was used to isolate PEG10, a potential miR-122 target implicated in HCC development. miR-122S binding sites in the PEG10 promoter were evaluated with a reporter assay. The regulation of PEG10 by miR-122S overexpression was examined by quantitative RT-PCR, western blotting, and immunohistochemistry in miR-122 knockout mice and liver tissue from HCC patients. The relationship between PEG10 expression and clinicopathologic features of HCC patients was also evaluated. RESULTS: miR-122 downregulated the expression of PEG10 protein through binding to 3′-untranslated region (UTR) of the PEG10 transcript. In miR-122 knockout mice and HCC patients, the deficiency of miR-122 was associated with HCC progression. The expression of PEG10 was increased in 57.3 % of HCC as compared to paired non-cancerous tissue samples. However, significant upregulation was detected in 56.5 % of patients and was correlated with Okuda stage (P = 0.05) and histological grade (P = 0.001). CONCLUSIONS: miR-122 suppresses PEG10 expression via direct binding to the 3′-UTR of the PEG10 transcript. Therefore, while PEG10 could not be an ideal diagnostic biomarker for HCC but its upregulation in HCC tissue still has predictive value for HCC prognosis.
format Online
Article
Text
id pubmed-4930569
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49305692016-07-03 miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma Shyu, Yu-Chiau Lee, Tung-Liang Lu, Mu-Jie Chen, Jim-Ray Chien, Rong-Nan Chen, Huang-Yang Lin, Ji-Fan Tsou, Ann-Ping Chen, Yu-Hsien Hsieh, Chia-Wen Huang, Ting-Shuo J Transl Med Research BACKGROUND: Hepatocellular carcinoma (HCC), a primary liver malignancy, is the most common cancer in males and fourth common cancer in females in Taiwan. HCC patients usually have a poor prognosis due to late diagnosis. It has been classified as a complex disease because of the heterogeneous phenotypic and genetic traits of the patients and a wide range of risk factors. Micro (mi)RNAs regulate oncogenes and tumor suppressor genes that are known to be dysregulated in HCC. Several studies have found an association between downregulation of miR-122, a liver-specific miRNA, and upregulation of paternally expressed gene 10 (PEG10) in HCC; however, the correlation between low miR-122 and high PEG10 levels still remains to be defined and require more investigations to evaluate their performance as an effective prognostic biomarker for HCC. METHODS: An in silico approach was used to isolate PEG10, a potential miR-122 target implicated in HCC development. miR-122S binding sites in the PEG10 promoter were evaluated with a reporter assay. The regulation of PEG10 by miR-122S overexpression was examined by quantitative RT-PCR, western blotting, and immunohistochemistry in miR-122 knockout mice and liver tissue from HCC patients. The relationship between PEG10 expression and clinicopathologic features of HCC patients was also evaluated. RESULTS: miR-122 downregulated the expression of PEG10 protein through binding to 3′-untranslated region (UTR) of the PEG10 transcript. In miR-122 knockout mice and HCC patients, the deficiency of miR-122 was associated with HCC progression. The expression of PEG10 was increased in 57.3 % of HCC as compared to paired non-cancerous tissue samples. However, significant upregulation was detected in 56.5 % of patients and was correlated with Okuda stage (P = 0.05) and histological grade (P = 0.001). CONCLUSIONS: miR-122 suppresses PEG10 expression via direct binding to the 3′-UTR of the PEG10 transcript. Therefore, while PEG10 could not be an ideal diagnostic biomarker for HCC but its upregulation in HCC tissue still has predictive value for HCC prognosis. BioMed Central 2016-07-02 /pmc/articles/PMC4930569/ /pubmed/27370270 http://dx.doi.org/10.1186/s12967-016-0956-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shyu, Yu-Chiau
Lee, Tung-Liang
Lu, Mu-Jie
Chen, Jim-Ray
Chien, Rong-Nan
Chen, Huang-Yang
Lin, Ji-Fan
Tsou, Ann-Ping
Chen, Yu-Hsien
Hsieh, Chia-Wen
Huang, Ting-Shuo
miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title_full miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title_fullStr miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title_full_unstemmed miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title_short miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma
title_sort mir-122-mediated translational repression of peg10 and its suppression in human hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930569/
https://www.ncbi.nlm.nih.gov/pubmed/27370270
http://dx.doi.org/10.1186/s12967-016-0956-z
work_keys_str_mv AT shyuyuchiau mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT leetungliang mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT lumujie mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT chenjimray mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT chienrongnan mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT chenhuangyang mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT linjifan mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT tsouannping mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT chenyuhsien mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT hsiehchiawen mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma
AT huangtingshuo mir122mediatedtranslationalrepressionofpeg10anditssuppressioninhumanhepatocellularcarcinoma